The impact of edema on planning 125I and 103Pd prostate implants

被引:53
|
作者
Yue, N
Dicker, AP
Nath, R
Waterman, FM
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA
关键词
brachytherapy; prostate implants; I-125; Pd-103; edema; dose evaluation; preimplant planning;
D O I
10.1118/1.598585
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Permanent transperineal interstitial I-125 and Pd-103 prostate implants are generally planned to deliver a specific dose to a clinically defined target volume; however, the post-implant evaluation usually reveals that the implant delivered a lower or higher dose than planned. This difference is generally attributed to such factors as source placement errors, overestimation of the prostate volume on CT, and post-implant edema. In the present work we investigate the impact of edema alone. In routine prostate implant planning, it is customary to assume that both the prostate and seeds are static throughout the entire treatment time, and post-implant edema is not taken into consideration in the dosimetry calculation. However, prostate becomes edematous after seed implantation, typically by 50% in volume [Int. J. Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998)]. The edema resolves itself exponentially with a typical half-life of 10 days. In this work, the impact of the edema-induced dynamic change in prostate volume and seed location on the dose coverage of the prostate is investigated. The total dose delivered to the prostate was calculated by use of a dynamic model, which takes edema into account. In the model, the edema resolves exponentially with time, as reported in a separate study based on serial CT scans [Int. J. Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998)]. The model assumes that the seeds were implanted exactly as planned, thus eliminating the effect of source placement errors. Implants based on the same transrectal ultrasound (TRUS) images were planned using both I-125 and Pd-103 sources separately. The preimplant volume and planned seed locations were expanded to different degrees of edema to simulate the postimplant edematous prostate on day 0. The model calculated the dose in increments of 24 h, appropriately adjusting the prostate volume, seed locations, and source strength prior to each time interval and compiled dose-volume histograms (DVH) of the total dose delivered. A total of 30 such DVHs were generated for each implant using different combinations of edema half-life and magnitude. In addition, a DVH of the plan was compiled in the conventional manner, assuming that the prostate volume and seeds were static during treatment. A comparison of the DVH of the static model to the 30 edema corrected DVHs revealed that the plan overestimated the total dose by an amount that increased with the magnitude of the edema and the edema half-life. The maximum overestimation was 15% for I-125 and 32% for (103)pd. For more typical edema parameters (a 50% increase in volume and a 10 day half-life) the static plan for I-125 overestimated the total dose by about 5%, whereas that for Pd-103 overestimated it by about 12%. (C) 1999 American Association of Physicists in Medicine. [S0094-2405(99)00705-1].
引用
收藏
页码:763 / 767
页数:5
相关论文
共 50 条
  • [31] Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water
    Wuu, Cheng-Shie
    Chen, Jing
    RADIATION PROTECTION DOSIMETRY, 2006, 122 (1-4) : 506 - 508
  • [32] Effect of 125I seeds and 103Pd stents on proliferation of vascular smooth muscle cells
    Zhu, Jun
    Luo, Quan-Yong
    Zhu, Rui-Sen
    Lu, Han-Kui
    Nuclear Science and Techniques/Hewuli, 2002, 13 (04):
  • [33] INVESTIGATING THE INFLUENCE OF DOSE IN THE EFFECTIVENESS OF PERMANENT BREAST BRACHYTHERAPY USING 125I OR 103PD SOURCES
    Lymperopoulou, G.
    Mavroidis, P.
    Baltas, D.
    Loffler, E.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S607 - S607
  • [34] Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models
    Thomson, R. M.
    Rogers, D. W. O.
    MEDICAL PHYSICS, 2010, 37 (01) : 368 - 376
  • [35] Updated Solid Water™ to water conversion factors for 125I and 103Pd brachytherapy sources.
    Awan, S.
    Meigooni, A.
    Dou, K.
    Dini, S.
    MEDICAL PHYSICS, 2006, 33 (06) : 2147 - 2147
  • [36] Ocular brachytherapy dosimetry for 103Pd and 125I in the presence of gold nanoparticles: a Monte Carlo study
    Asadi, Somayeh
    Vaez-zadeh, Mehdi
    Vahidian, Mohammad
    Marghchouei, Mahdieh
    Masoudi, S. Farhad
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2016, 17 (03): : 90 - 99
  • [37] Ocular Brachytherapy Dosimetry for 103Pd and 125I in The Presence of Gold Nanoparticles: Monte Carlo Study
    Asadi, S.
    Vaez-zadeh, M.
    Vahidian, M.
    Marghchouei, M.
    Masoudi, S. Farhad
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 : S105 - S105
  • [38] COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I, and 131Cs
    Melhus, Christopher S.
    Rivard, Mark J.
    MEDICAL PHYSICS, 2008, 35 (07) : 3364 - 3371
  • [39] Dosimetric Comparison of Water and Complete Eye Definition Phantoms for 125I and 103Pd Brachytherapy Plaques
    Rostami, Zohreh Dehghannia
    Masoudi, Seyed Farhad
    Asadi, Somayeh
    Iranian Journal of Medical Physics, 2011, 8 (02):
  • [40] New 125I and 103Pd brachytherapy seed air-kerma-strength measurement techniques
    Culberson, WS
    Selbach, HJ
    Kramer, HM
    DeWerd, LA
    MEDICAL PHYSICS, 2004, 31 (06) : 1713 - 1713